Literature DB >> 7655816

Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate.

D M Williams1, K C Carter, A J Baillie.   

Abstract

Five non-ionic surfactants (Surfactants V-IX) were screened for their ability to produce vesicles for the delivery of sodium stibogluconate. Mean vesicle diameter and antimony content were determined prior to in vivo assessment of antiparasitic activity in a mouse model of acute visceral leishmaniasis. V/D suspensions (i.e. stibogluconate loaded vesicles kept in the hydrating drug solution) were more effective against spleen, liver and bone marrow parasites than drug loaded vesicle suspensions that had unentrapped drug removed. A Surfactant IX V/D suspension was the most active antileishmanial preparation causing 74 +/- 10%, 99 +/- 1% and 38 +/- 8% suppression of liver, spleen and bone marrow parasite burdens respectively. Contrary to previous findings, a reduction in splenic and bone marrow parasite burdens was achieved using large vesicles (mean diameter > 800nm). The significance of these results is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7655816     DOI: 10.3109/10611869509015926

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

1.  Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: in vitro and in vivo evaluation.

Authors:  Sabyasachi Maiti; Sayon Paul; Ranjit Mondol; Somasree Ray; Biswanath Sa
Journal:  AAPS PharmSciTech       Date:  2011-06-14       Impact factor: 3.246

2.  Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.

Authors:  K C Carter; A B Mullen; S Sundar; R T Kenney
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

3.  Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.

Authors:  J Nieto; J Alvar; A B Mullen; K C Carter; C Rodríguez; M I San Andrés; M D San Andrés; A J Baillie; F González
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

4.  The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.

Authors:  K C Carter; A J Baillie; A B Mullen
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

5.  Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.

Authors:  A B Mullen; A J Baillie; K C Carter
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.